Novo Nordisk discontinued its experimental AERx inhaler and took a charge of $260 million in 2007, saying the product offered little clinical benefit. "Pfizer's decision on Exubera prompted this," Mads Krogsgaard Thomsen, Novo's chief scientific officer, said in a publi...

Viadur[TM] (leuprolide acetate implant), providing a sustained release of drug over a 12- month duration, decreases serum testosterone in advanced prostate cancer patients, providing long-term, palliative medical hormonal therapy Clinical experience suggests Viad...